The KRAS (G12C) inhibitor adagrasib induced an objective response in about one out of three patients with previously treated KRAS (G12C)–mutated non–small cell lung cancer (NSCLC).
Medscape Medical News
New KRAS Inhibitor Shows Promise in NSCLC
The KRAS (G12C) inhibitor adagrasib induced an objective response in about one out of three patients with previously treated KRAS (G12C)–mutated non–small cell lung cancer (NSCLC).
Medscape Medical News
